The USA based pharma-focused CDMO, PCI Pharma Services, has announced a $365 million investment in USA and EU operations. The investment is intended to focus on infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats.

As part of the investment, the company plans a 545 thousand square foot expansion at its Rockford, Illinois campus which will be dedicated to advanced drug delivery and drug-device combination assembly and packaging. The plan will be advanced in two phases with operations expected to commence in Q3 2025, with highlights including:

• 345 thousand square feet for advanced drug delivery injectable packaging
• 130 thousand square feet of warehousing for products in all development phases
• 70 thousand square feet dedicated to advanced drug delivery and patient-centric drug-device combination assembly and packaging

In addition, the company has acquired a pharmaceutical packaging and device assembly facility near Dublin, Ireland, which provides large-scale temperature-controlled storage capabilities. Operations are scheduled to commence in Q4 2024, with the facility providing commercial-scale packaging and assembly operations for injectables as well as oral solid dose drug products. PCI has also begun construction of a new packaging and device assembly services facility at its CityNorth Dublin campus, with operations expected to begin in Q3 2025. The plant will provide increased capacity for the final assembly, labelling and packaging of injectable drug products including vials, prefilled syringes, and drug-device combination products such as autoinjectors. The facility also will include cold chain packaging for injectable and biologic products, as well as associated temperature-controlled storage.